BMS-5
| Code | Size | Price |
|---|
| SYN-1024-M100 | 100 mg | Enquire |
Quantity:
| SYN-1024-M001 | 1 mg | £104.00 |
Quantity:
| SYN-1024-M005 | 5 mg | £151.00 |
Quantity:
| SYN-1024-M010 | 10 mg | £221.00 |
Quantity:
| SYN-1024-M050 | 50 mg | £654.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
-20°C
Documents
Further Information
Alternate Names/Synonyms:
BMS5
Appearance:
Solid.
CAS:
1338247-35-0
EClass:
32160000
Form (Short):
liquid
InChi:
InChI=1S/C17H14Cl2F2N4OS/c1-8(2)16(26)23-17-22-7-13(27-17)12-6-11(15(20)21)24-25(12)14-9(18)4-3-5-10(14)19/h3-8,15H,1-2H3,(H,22,23,26)
InChiKey:
IVUGBSGLHRJSSP-UHFFFAOYSA-N
Long Description:
Chemical. CAS: 1338247-35-0. Formula: C17H14Cl2F2N4OS. MW: 431.3. Kinases, such as LIM kinase 1 (LIMK1) and LIM kinase 2 (LIMK2), have been identified as participating in signal pathways affecting actin dynamics by deactivating cofilin. Over expression of LMK1 has been found in invasive breast and prostate cancer cell lines and suppression of LIMK 2 expression has been found to limit migration of human fibrosarcoma cells. Thus, the inhibition of LIMK1 and/or LIMK2 enzymes have been suggested as targets for treating cancer, including reduction or prevention of metastasis. BMS-5 is a potent inhibitor of the LIM kinase. It has IC(50) values of 7nM and 8nM for LIMK1 and LIMK2 respectively. LIMK1/2 activity was measured via TCA precipitation assay using a biotinylated ADF (actin depolymization factor) as the protein substrate and the kinase domains of LIMK1 and LIMK2 as the enzyme sources in the presence of 1µM ATP.
Molecular Formula:
C17H14Cl2F2N4OS
Molecular Weight:
431.3
Package Type:
Plastic Vial
Product Description:
Kinases, such as LIM kinase 1 (LIMK1) and LIM kinase 2 (LIMK2), have been identified as participating in signal pathways affecting actin dynamics by deactivating cofilin. Over expression of LMK1 has been found in invasive breast and prostate cancer cell lines and suppression of LIMK 2 expression has been found to limit migration of human fibrosarcoma cells. Thus, the inhibition of LIMK1 and/or LIMK2 enzymes have been suggested as targets for treating cancer, including reduction or prevention of metastasis. BMS-5 is a potent inhibitor of the LIM kinase. It has IC(50) values of 7nM and 8nM for LIMK1 and LIMK2 respectively. LIMK1/2 activity was measured via TCA precipitation assay using a biotinylated ADF (actin depolymization factor) as the protein substrate and the kinase domains of LIMK1 and LIMK2 as the enzyme sources in the presence of 1µM ATP.
Purity:
>95%
Solubility Chemicals:
Soluble in DMSO.
Transportation:
Non-hazardous
UNSPSC Category:
Protein Kinase Modulators
UNSPSC Number:
12352200
Use & Stability:
Stable for at least 2 years after receipt when stored at -20°C.
References
Phenyl-substituted pyrimidine compounds useful as kinase inhibitors: S.T. Wrobelski, et al.; WO2006084017 (2006) | Computer-Based Identification of a Novel LIMK1/2 Inhibitor that Synergizes with Salirasib to Destabilize the Actin Cytoskeleton: E. Mashiach-Farkash, et al.; Oncotarget 3, 629 (2012) | LIM kinase regulation of cytoskeletal dynamics is required for salivary gland branching morphogenesis: S. Ray, et al.; Mol. Biol. Cell 25, 2393 (2014)